A BILL 
To amend the Public Health Service Act to shorten the 
exclusivity period for brand name biological products 
from 12 to 5 years. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Price Relief, Innova-
4
tion, and Competition for Essential Drugs Act’’ or the 
5
‘‘PRICED Act’’. 
6
16:03 May 23, 2022
H7828
2 
•HR 7828 IH
SEC. 2. EXCLUSIVITY PERIOD FOR BRAND NAME BIOLOGI-
1
CAL PRODUCTS. 
2
(a) IN GENERAL.—Section 351(k)(7)(A) of the Pub-
3
lic Health Service Act (42 U.S.C. 262(k)(7)(A)) is amend-
4
ed by striking ‘‘12 years’’ and inserting ‘‘5 years’’. 
5
(b) CONFORMING CHANGES.—Paragraphs (2)(A) and 
6
(3)(A) of section 351(m) of the Public Health Service Act 
7
(42 U.S.C. 262(m)) is amended by striking ‘‘12 years’’ 
8
each place it appears and inserting ‘‘5 years’’. 
9
(c) APPLICABILITY.—This Act and the amendments 
10
made by this Act apply only with respect to a biological 
11
product for which the reference product (as such term is 
12
used in section 351 of the Public Health Service Act (42 
13
U.S.C. 262)) is licensed under subsection (a) of such sec-
14
tion on or after the date of enactment of this Act. 
15
Æ 
16:03 May 23, 2022
H7828
